$ATAI 0.57 Developing

Notable posts

• @wallstengine neutral 294 eng

  Eli Lilly $LLY is reportedly in talks to acquire psychedelic drugmaker AtaiBeckley $ATAI, per Bloomberg. A deal could be announced as soon as this week. AtaiBeckley has a market value of about $2B, and Lilly is reportedly negotiating at a premium. The key asset is BPL-003, a fast-acting nasal spray for treatment-resistant depression that has FDA Breakthrough Therapy designation. Bloomberg Intelligence estimates the psychedelic treatment market could reach $7B in sales by 2032.

  view on X →
• @wallstengine neutral 162 eng

  Eli Lilly $LLY agreed to acquire AtaiBeckley $ATAI for up to $3.8B. Terms: $6.75/share cash upfront, valuing AtaiBeckley at about $2.8B, plus a CVR worth up to $2.50/share tied to BPL-003 and VLS-01 milestones. The upfront price is a roughly 40% premium to $ATAI’s 30-day VWAP. Key asset: BPL-003, an intranasal 5-MeO-DMT therapy for treatment-resistant depression with FDA Breakthrough Therapy designation and Phase 3 activity underway. Deal expected to close in Q3 2026.

  view on X →
• @wallstengine neutral 42 eng

  $ATAI says AtaiBeckley dosed the last patient in its Phase 2b Elumina trial of VLS-01 for treatment-resistant depression. Topline data expected in Q4 2026. Trial details: 156 patients Randomized 1:1 vs placebo Primary endpoint: MADRS change at Day 29 VLS-01 is an oral transmucosal DMT formulation If Phase 2b data are supportive, AtaiBeckley plans to move VLS-01 into Phase 3 for major depressive disorder, with generalized anxiety disorder as a potential follow-on indication.

  view on X →
• @wallstengine bullish 39 eng

  Canaccord Raises $ATAI PT to $17 from $15 - Buy Analyst comments: "Plans for VLS-01 in major depressive disorder make a lot of sense to us. Earlier today, July 6, ATAI announced it had dosed the last patient in its Elumina Phase 2 trial for VLS-01, a DMT buccal film, for treatment-resistant depression (TRD), and reiterated its timeline for top-line data in 4Q26. Based on the data, the company now expects to advance VLS-01 into Phase 3 trials for major depressive disorder (MDD), after which it could expand into generalized anxiety disorder (GAD). We are not entirely surprised by this planned move into MDD for VLS-01, given lead candidate BPL-003, intranasal mebufotenin or 5-MeO-DMT, is already in a Phase 3 program for TRD, and TRD is essentially a subset of MDD. Importantly, VLS-01 also fits into a two-hour treatment session paradigm. We also note this move into MDD opens up a larger patient pool for VLS-01 and could lead to faster enrollment in Phase 3 trials versus TRD, where patients have to fail at least two standard antidepressants in the current depressive episode to enroll. Separately, ATAI expects BPL-003 top-line Phase 3 data in 2029. Of course, for VLS-01 to advance into Phase 3 in MDD, we still need solid Phase 2b data in TRD. Heading into Elumina data in 4Q26, we like the product's chances as 5-HT2A receptor agonists, such as DMT, LSD, and psilocybin, are generally known to work in this setting. Longer term, we still view ATAI as significantly undervalued versus the size of the unmet need and market opportunity in the mental health-focused indications it is targeting. Reiterate Buy." Analyst: Sumant Kulkarni

  view on X →
• @tenet_research neutral 20 eng

  Tenet Market Wake-Up Summary 📷📷 July.16.26 $SPX $ASTS $LLY $ATAI $MU $SNDK $SKHY $STX $WDC $LMT $RTX $NOC $NVDA $EOSE $APLD $UBER $CDNA $TSM $UNH $ABT $MAN $JBHT $CBSH $FEM $GE $IIIN $UAL $STT $RKT $AVAV $BLK $CTAS $SPCX $GOOGL $RMD $WRB $AEP $PNR $VEEE $CMPS $BE @ripster47 | @TENETTRADEGROUP | @TenetCharts

  view on X →